We bring drug development programs into our pipeline as early as candidate selection and advance candidates to an appropriate value inflection point.

Our team of scientists and clinicians have expertise across multiple disease areas, mechanisms, and molecule types. We are data-driven and rigorously pursue a thorough understanding of the biology, mechanism, and potential therapeutic differentiation before committing to a program.

Translational Medicine Focus

We believe in three principles:

Our industry suffers from a chronic mismatch between the flow of innovation and resource availability at any point in time.
Access to development expertise and appropriate funding can be the key catalyst for drug development programs to reach their full potential.
The demonstration of true clinical proof-of-concept is a key value-creation step in the clinical development of a medicine.

Our expert team designs and leads our programs.

Complementing the Boston Pharmaceuticals team is a network of best-in-class development partners strategically integrated into our programs. This blended model allows us to flexibly scale across programs, return more value to our partners and ultimately bring the best medicines to patients.

Boston - Model BOS-857 - Small Molecule Furin Inhibitor

Asset Overview